Medpace (NASDAQ:MEDP) Stock Price Down 0.1%

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) traded down 0.1% during trading on Friday . The stock traded as low as $388.88 and last traded at $389.46. 28,702 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 249,331 shares. The stock had previously closed at $389.77.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Guggenheim upped their price objective on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday. Robert W. Baird upped their price objective on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and upped their target price for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Finally, StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $443.00.

Medpace Stock Performance

The stock’s 50-day simple moving average is $397.75 and its 200 day simple moving average is $324.12. The company has a market capitalization of $12.27 billion, a PE ratio of 39.70, a P/E/G ratio of 1.98 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company’s revenue was up 17.7% on a year-over-year basis. During the same period last year, the firm posted $2.27 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 102 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The disclosure for this sale can be found here. Insiders have sold 189,340 shares of company stock valued at $76,651,647 in the last ninety days. Insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP lifted its stake in shares of Medpace by 312.6% in the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after acquiring an additional 319,210 shares during the period. TD Asset Management Inc lifted its stake in shares of Medpace by 195.2% in the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after acquiring an additional 308,816 shares during the period. Invesco Ltd. lifted its stake in shares of Medpace by 67.6% in the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after acquiring an additional 246,775 shares during the period. Norges Bank acquired a new stake in shares of Medpace in the 4th quarter worth $59,163,000. Finally, Epoch Investment Partners Inc. lifted its stake in shares of Medpace by 82.3% in the 4th quarter. Epoch Investment Partners Inc. now owns 352,463 shares of the company’s stock worth $108,040,000 after acquiring an additional 159,144 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.